Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · IEX Real-Time Price · USD
19.74
+0.81 (4.28%)
At close: Apr 26, 2024, 4:00 PM
19.42
-0.32 (-1.62%)
After-hours: Apr 26, 2024, 7:13 PM EDT

Akero Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current20232022202120202019
Market Capitalization
1,3611,3012,563738896634
Market Cap Growth
--49.24%247.29%-17.63%41.33%-
Enterprise Value
8377772,222551629497
PE Ratio
-8.57-8.57-22.87-7.32-11.31-14.49
PB Ratio
2.542.437.854.363.464.92
P/FCF Ratio
-8.95-8.95-27.70-9.26-12.63-17.79
P/OCF Ratio
-8.95-8.95-27.70-9.26-12.65-17.79
EV/EBITDA Ratio
-5.23-5.23-20.01-5.48-7.96-11.37
EV/EBIT Ratio
-5.22-5.22-19.96-5.47-7.94-11.37
EV/FCF Ratio
-5.34-5.34-24.01-6.91-8.86-13.96
Debt / Equity Ratio
0.050.050.030.010.01-
Debt / EBITDA Ratio
-0.17-0.17-0.10-0.01-0.02-
Debt / FCF Ratio
-0.18-0.18-0.11-0.02-0.02-
Quick Ratio
28.7528.7518.427.4920.4714.56
Current Ratio
29.2729.2718.617.7020.7014.74
Interest Coverage
-47.97-47.97-150.60---
Return on Equity (ROE)
-29.70%-29.70%-46.40%-48.30%-41.30%-46.60%
Return on Assets (ROA)
-27.20%-27.20%-41.10%-44.10%-38.90%-33.40%
Return on Capital (ROIC)
-30.81%-30.81%-34.15%-59.20%-30.80%-35.46%
Earnings Yield
-11.15%-11.67%-4.37%-13.66%-8.84%-6.90%
FCF Yield
-10.68%-11.17%-3.61%-10.80%-7.92%-5.62%
Buyback Yield / Dilution
-34.84%-34.84%-11.94%-10.69%-108.77%-14474.75%
Total Shareholder Return
-34.84%-34.84%-11.94%-10.69%-108.77%-14474.75%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).